Five-Year Review of HIV-Hepatitis B Virus (HBV) Co-Infected Patients in a New York City AIDS Center.
10.3346/jkms.2012.27.7.830
- Author:
Jong Hun KIM
1
;
George PSEVDOS
;
Victoria SHARP
Author Information
1. Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
- Publication Type:Brief Communication
- Keywords:
HIV;
Hepatitis B Virus;
Mortality
- MeSH:
Adenine/analogs & derivatives/therapeutic use;
Adult;
Anti-HIV Agents/therapeutic use;
Coinfection/drug therapy/mortality;
Female;
HIV Infections/complications/*diagnosis/drug therapy;
Hepatitis B/complications/*diagnosis/drug therapy;
Hepatitis B e Antigens/blood;
Humans;
Liver Cirrhosis/etiology;
Male;
Middle Aged;
New York City;
Organophosphonates/therapeutic use;
Retrospective Studies
- From:Journal of Korean Medical Science
2012;27(7):830-833
- CountryRepublic of Korea
- Language:English
-
Abstract:
A retrospective review of 4,721 human immunodeficiency virus (HIV)-infected patients, followed at St. Luke's Roosevelt Hospital Center, New York City, was conducted from January 1, 2005 to December 31, 2009. HIV-Hepatitis B virus (HBV) co-infection rate was 218/4,721, 4.6%. Among co-infected patients, 19 patients (19/218, 8.7%) died; 13 patients (13/19, 68.4%) died from non-acquired immune deficiency syndrome (AIDS) defining including 2 patients with liver failure. More non-survivors (5 patients, 5/19, 26.3%) had liver cirrhosis than those who survived (8 patients, 8/199, 4.0%; P = 0.002). There were more patients with positive HBV e antigen (HBeAg) among non-survivors, (12 patients, 12/19, 63.2%) than among survivors (74 patients, 74/199, 37.2%; P = 0.047). HIV-HBV co-infection is associated with increased overall mortality. Therefore, use of dual active antiretrovirals, particularly, tenofovir (TDF) based regimen for optimal suppression of HIV-HBV and immune restoration with prevention of high risk behaviors may contribute to improved outcomes.
